Analyst firms · Citizens JMP · ACAD

Citizens JMP ACAD price target and rating history

ACADIA Pharmaceuticals Inc. (ACAD) · Health Care

Citizens JMP rates ACADIA Pharmaceuticals Inc. (ACAD) Market Outperform with a $35 price target, as of its latest action on Mar 1, 2022. It has published 4 rating actions on ACAD since December 2021, including 0 upgrades and 0 downgrades. Across 4 firms with a ACAD price target in the last 12 months, the median target is $31.

Current rating
Market Outperform
Price target
$35
Median target, all firms
$31
Actions on ACAD
4

Citizens JMP price target on ACAD

$42$39$3520222023202420252026
Citizens JMP price target on ACAD, each point a stated target, December 2021 to March 2022.

Every Citizens JMP rating on ACAD

How other firms rate ACAD

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
UBSNeutral$23Oct 13, 2026
BofA SecuritiesBuy$29Mar 25, 2026
Wolfe ResearchOutperform$33Feb 24, 2026
MizuhoOutperform$35Feb 23, 2026

Questions about Citizens JMP and ACAD

What is Citizens JMP's price target for ACAD?
Citizens JMP's latest stated price target for ACADIA Pharmaceuticals Inc. (ACAD) is $35, from its action on Mar 1, 2022.
What is Citizens JMP's rating on ACAD?
Citizens JMP rates ACAD Market Outperform, a bullish rating, as of Mar 1, 2022.
When did Citizens JMP last change its view on ACAD?
On Mar 1, 2022, Citizens JMP cuts its price target to $35 from $42, keeps Market Outperform.
How does Citizens JMP's ACAD target compare with other analysts?
Across 4 firms with a ACAD price target in the last 12 months, the median target is $31.

More ACAD rating histories

All Citizens JMP ratingsACAD news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.